| 펩트론, 기업 소개 | 2024-11-22T08:10:56.295829+00:00 |
| 펩트론, 기업 소개 | 2024-11-21T08:08:01.677289+00:00 |
| 펩트론, 한국경제신문 주최 2024 한경바이오인사이트 포럼 행사 참가 | 2024-03-06T08:08:29.401990+00:00 |
| 펩트론, 2023 Kiwoom Corporate Day 참가 | 2023-09-22T05:11:42.524578+00:00 |
| 펩트론, 2023 Kiwoom Corporate Day 참가 | 2023-09-21T08:10:22.828863+00:00 |
| 펩트론, 회사 소개 및 주요 사업현황에 대한 투자자 이해 증진 | 2023-07-17T04:10:16.254899+00:00 |
| 펩트론-펩트론-뇌질환-치료제-PT320-글로벌-임상3상-첫-투약-개시 | 2022-11-21T05:34:16+00:00 |
| 펩트론-펩트론-전립선암-치료제-PT105-생동성-임상-최초-성공판권-계약-초읽기 | 2022-11-18T07:43:00+00:00 |
| 펩트론-펩트론-전립선암-치료제-PT105-생동성-임상-최초-성공판권-계약-초읽기 | 2022-11-17T06:42:50+00:00 |
| 펩트론-펩트론-결손금-보전-통한-이익잉여금-확보주주친화정책-마련 | 2022-10-21T00:42:27+00:00 |
| 펩트론-펩트론-스마트데포-기술-의약품-첫-FDA-3상-승인 | 2022-08-22T00:42:24+00:00 |
| 펩트론-펩트론-MUC1-특이적-결합-항체-PAb001-미국-특허-등록- | 2022-07-19T05:42:32+00:00 |
| 펩트론-펩트론-뇌질환-치료제-프리센딘-영국에-이어-호주-임상3상-IND-승인 | 2022-07-08T08:43:29+00:00 |
| 펩트론-펩트론-뇌질환-치료제-프리센딘-영국에-이어-호주-임상3상-IND-승인 | 2022-07-07T00:44:39+00:00 |
| 펩트론-펩트론-파킨슨병-치료제-PT320-국내-식약처-치료목적-사용승인 | 2022-06-29T06:42:57+00:00 |
| 펩트론-펩트론-호주-인벡스사와-공동개발-중인-뇌질환-치료제-프리센딘-영국-임상3상-IND-승인임상개시 | 2022-06-29T06:42:39+00:00 |
| 펩트론-펩트론-파킨슨병-치료제-PT320-국내-식약처-치료목적-사용승인 | 2022-06-27T03:41:20+00:00 |
| 펩트론-펩트론-파킨슨병-치료제-미국-특허-취득 | 2022-05-17T00:42:50+00:00 |
| 펩트론-펩트론-회사소개-및-파이프라인별-연구개발현황-및-향후계획 | 2022-04-28T00:42:24+00:00 |
| 펩트론-펩트론-신한-헬스케어-포럼-참석 | 2022-04-08T05:42:38+00:00 |